OUR TEAM

Our leadership team possesses rich and diverse industry knowledge, a passion for science and a shared commitment to help transform lives.

Made up of our founding scientists, industry experts, Nobel Laureates and members of the National Academy of Sciences, we consistently push the boundaries of scientific excellence and discovery.

  • Leonard S. Schleifer, MD, PhD: Founder, President & Chief Executive Officer

    Leonard S. Schleifer, MD, PhD

  • George D. Yancopoulos, MD, PhD: Founding Scientist, President & Chief Scientific Officer

    George D. Yancopoulos, MD, PhD

  • Co-Founder, President and Chief Executive Officer

    Leonard S. Schleifer, MD, PhD, founded Regeneron in 1988, has been a Director and the company's President and Chief Executive Officer since its inception. He served as Chairman of the Board from 1990 through 1994. Dr. Schleifer, together with Dr. Yancopoulos, has grown Regeneron from a tiny startup into a ~$50 billion market cap company, with a unique science-driven culture, successful drug discovery and development engine and eight FDA-approved medicines. Dr. Schleifer has been recognized as one of Barron’s Best CEOs and as an Ernst & Young Entrepreneur of the Year. He graduated from Cornell University and earned his MD and PhD in Pharmacology from the University of Virginia. Dr. Schleifer is a licensed physician, certified in Neurology by the American Board of Psychiatry and Neurology, and worked as a practicing neurologist before founding Regeneron.

  • Co-Founder, President and Chief Scientific Officer

    George D. Yancopoulos, MD, PhD, has built and managed Regeneron alongside Dr. Schleifer since 1989. Dr. Yancopoulos is currently President and Chief Scientific Officer and has served on the board since 2001. Dr. Yancopoulos, along with key members of his team, is the principal inventor of Regeneron’s eight FDA-approved drugs and foundational technologies, including the TRAP technology, VelociGene® and VelocImmune®. He has been named an Ernst & Young Entrepreneur of the Year and has been pivotal in creating the science-driven, collaborative and highly-productive R&D culture at Regeneron. This unique environment has earned the company widespread recognition, including repeatedly being named one of the "most innovative companies in the world" by Forbes magazine. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos attended the Bronx High School of Science and received his MD and PhD from Columbia University.

  • Corporate Leaders

  • Maya Bermingham

    Maya Bermingham

  • Chris Fenimore

  • Beth F. Holly: Senior Vice President, Associate General Counsel, Chief Compliance Officer

    Beth F. Holly

  • Senior Vice President, Public Policy & Government Affairs

    Maya Bermingham, JD, joined Regeneron in 2015 and serves as Senior Vice President, Public Policy and Government Affairs. Ms. Bermingham and her Washington, DC-based team play a critical role in helping Regeneron shape and maintain its industry-leading reputation among governmental stakeholders. In 2020, Ms. Bermingham stepped forward to also serve as the company’s interim head of Diversity, Equity and Inclusion (DE&I). Prior to joining Regeneron, Ms. Bermingham held roles of increasing responsibility at PhRMA over a 12 year tenure, following earlier positions at legal firms, and work for Senator Moynihan and the Senate Finance Committee. She received her BA from Harvard University and her JD from New York University.

  • Senior Vice President, Head of Accounting and Controller

    Chris Fenimore joined Regeneron in 2003 and, as the current Head of Accounting and Controller, has global responsibility for SEC reporting, accounting and accounting operations, and internal control over financial reporting, administration of financial systems, accounts payable and payroll. Prior to his current role, he served as Regeneron’s Vice President of Financial Planning, and prior to joining Regeneron, he was Vice President of Finance at Mojave Therapeutics, Inc. He has prior experience in healthcare industry-focused venture capital and investment banking roles, as well as serving as an audit senior at KPMG. Mr. Fenimore holds an MA in Biotechnology from Columbia University, an MBA in Professional Accounting from Rutgers Business School and a BA in Economics from Rutgers University. Mr. Fenimore is a Certified Public Accountant in the State of New York. 

  • Senior Vice President, Associate General Counsel and Chief Compliance Officer

    Beth F. Holly joined Regeneron in 2008 and serves as Senior Vice President, Associate General Counsel and Chief Compliance Officer. Prior to joining Regeneron, Ms. Holly spent 13 years at Pfizer Inc., where she served in various positions in the Legal Division, culminating in the role of General Counsel - U.S. Pharmaceuticals, followed by 18 months at Keryx Biopharmaceuticals, Inc. as General Counsel and Chief Compliance Officer. In the early days of her legal career, Ms. Holly was a litigation associate at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison, following a judicial clerkship with U.S. District Judge Gerard L. Goettel of the Southern District of New York. Ms. Holly received a BS from Cornell University and a JD degree from Fordham Law School.

  • Nouhad Husseini: Senior Vice President, Business Development

    Nouhad Husseini

  • Robert E. Landry: Executive Vice President, Finance and Chief Financial Officer

    Robert E. Landry

  • Joseph J. LaRosa: Executive Vice President, General Counsel and Secretary

    Joseph J. LaRosa

  • Senior Vice President, Business Development

    Nouhad Husseini joined Regeneron in 2011 and is head of Business Development, overseeing the company’s efforts to execute new strategic collaborations and licensing agreements. He has nearly 20 years of experience in the biopharmaceutical industry, where he has held a variety of strategic, business development and finance roles, including in Genentech’s Business Development and Corporate Finance departments and in investment banking and equity research at Morgan Stanley and Robertson Stephens. Mr. Husseini received his undergraduate degree in Molecular Biology from Princeton University and MBA from the Wharton School at University of Pennsylvania.

  • Executive Vice President, Finance and Chief Financial Officer

    Robert E. Landry joined Regeneron in 2013 and serves as Executive Vice President, Finance and Chief Financial Officer. Prior to joining Regeneron, Mr. Landry served as Senior Vice President and Treasurer of Pfizer Inc. Mr. Landry also held a variety of U.S. and international financial and general management positions at Wyeth Pharmaceuticals, Pfizer and PricewaterhouseCoopers LLP, including at Wyeth's Australian and New Zealand affiliates. He holds a BBA in Accounting from the University of Notre Dame.

  • Executive Vice President, General Counsel and Secretary

    Joseph J. LaRosa joined Regeneron in 2011 and is currently Executive Vice President, General Counsel and Secretary. Prior to joining Regeneron, Mr. LaRosa was Senior Vice President, General Counsel and Secretary at Nycomed U.S., Inc. He also previously served as Vice President, Global Compliance and Legal Affairs at Avon Products, Inc., and held a number of senior legal positions at Schering-Plough Corporation, where he was a corporate officer and served as Vice President, Legal Affairs, and a member of the Operations Management Team. Mr. LaRosa received his JD degree from New York University.

  • Marion McCourt: Senior Vice President, Commercial

    Marion McCourt

  • Bob McCowan

    Bob McCowan

  • >Gonzalo Merino, PhD

    Gonzalo Merino, PhD

  • Senior Vice President, Commercial

    Marion McCourt joined Regeneron in 2018 and serves as Senior Vice President and Head of the Commercial organization. Prior to joining Regeneron, Ms. McCourt worked at Axovant, a clinical-stage biopharmaceutical company, where she was President and Chief Operating Officer. She served as Chief Operating Officer of Medivation until it was acquired by Pfizer Inc. in 2016, and before that held commercial leadership roles at Amgen, including Vice President in U.S. Commercial Operations and Vice President and General Manager responsible for the company’s bone health and primary care business unit. Ms. McCourt began her career and spent 12 years at AstraZeneca, ultimately becoming Chief Operating Officer for AstraZeneca U.S. She received her BS from Lafayette College.

  • Senior Vice President, IT and Chief Information Officer

    Bob McCowan is Senior Vice President and Chief Information Officer at Regeneron. With over 30 years global experience, Mr. McCowan leads the company’s IT organization and is responsible for global IT strategy supporting Research, Commercial, Cyber Security and Enterprise operations. He has driven an enhanced company focus on big data, innovation and strategic IT investments that support Regeneron’s mission. Mr. McCowan previously worked at international organizations including Amgen, Artemis International, Computer Science Corporation and Lockheed. He earned his MBA with the UK Open University and holds a degree in Electrical Engineering.

  • Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel

    Gonzalo Merino, PhD, JD, joined Regeneron in 2013 and now serves as Senior Vice President and Chief Intellectual Property Counsel. He is responsible for protecting Regeneron’s Intellectual Property, including by developing and implementing a comprehensive global IP strategy. Prior to joining Regeneron, Dr. Merino was an Associate General Counsel at Columbia University and a patent attorney at Bryan Cave LLP in New York City. He obtained his JD from Columbia University Law School, where he was a Harlan Fisk Stone Scholar, and his PhD from the Integrated Program in Cellular, Molecular and Biophysical Studies at the Columbia University Graduate School of Arts and Sciences, where he received the Richard C. Parker Award for Outstanding and Innovative Research and a Minority Pre-doctoral Fellowship Award.

  • Hala Mirza: Senior Vice President, Corporate Communications & Citizenship

    Hala Mirza

  • Sally A. Paull: Senior Vice President, Human Resources

    Sally A. Paull

  • Smita Pillai, Chief Diversity, Equity & Inclusion Officers

    Smita Pillai

  • Senior Vice President, Corporate Communications and Citizenship

    Hala Mirza joined Regeneron in 2014 and serves as Senior Vice President, Corporate Communications and Citizenship, leading corporate reputation, internal and external communications, patient advocacy and corporate citizenship. Before joining Regeneron, she was Vice President, Corporate Affairs for R&D and Strategy at Pfizer Inc. Prior to joining Pfizer, Ms. Mirza was Managing Director at W2O Group, a leading healthcare communications agency. She also previously served as Public Relations Officer at the American Red Cross Biomedical Services. Ms. Mirza received her BA from The George Washington University.

  • Senior Vice President, Human Resources

    Sally A. Paull joined Regeneron as Senior Vice President, Human Resources in 2016. She was previously Executive Vice President, Chief Human Resources Officer at Inova Health System. Prior to Inova, Ms. Paull was Senior Vice President, Chief Human Resources Officer at Forest Laboratories. Earlier in her career, Ms. Paull served in progressively senior human resources roles at DENYSPLY International. She received her BS from the United States Air Force Academy and her Master’s in International Relations from the University of Delaware.

  • Chief Diversity, Equity & Inclusion Officer

    Smita Pillai joined Regeneron as our first Chief Diversity, Equity & Inclusion (DE&I) Officer in 2021. Ms. Pillai has an accomplished global DE&I career spanning Life Sciences, Technology, Financial Services and Media sectors. Most recently she was VP, Global Head of DE&I at Zendesk. Prior to that she was Chief Diversity Officer for Dow Jones, including its flagship brand The Wall Street Journal. Before that, she has led global marketing research, corporate strategy and DE&I efforts at Fortune 50 companies such as Prudential Financial, Johnson & Johnson and ACNielsen. A certified DE&I professional, Ms. Pillai received her BBA from KS School of Management and MBA from Symbiosis International Business School, India.

  • Kerry Reinertsen, PhD: Senior Vice President, Strategic Alliances

    Kerry Reinertsen, PhD

  • Deb Tegan

    Deborah Tegan

  • Senior Vice President, Strategic Alliances

    Kerry Reinertsen, PhD, joined Regeneron in 2011 and serves as Senior Vice President of Strategic Alliances. Prior to joining Regeneron, she was Chief Business Officer of Constellation Pharmaceuticals. Before this, Dr. Reinertsen served as the Vice President of Corporate Development at Vertex Pharmaceuticals. Dr. Reinertsen started her biotech career at Millennium Pharmaceuticals (now Takeda Oncology) where she held positions of increasing responsibility in business development. Dr. Reinertsen received her PhD in Biological Chemistry and Molecular Pharmacology from Harvard University and her ScB in Molecular Biology and AB in Economics from Brown University.

  • Senior Vice President, Strategic Sourcing and Procurement

    Deborah Tegan joined Regeneron in 2006 and serves as Senior Vice President, Strategic Sourcing and Procurement. Prior to joining Regeneron, Ms. Tegan worked at Ciba Specialty Chemicals and then as Senior Director/Head of Procurement at Purdue Pharma L.P., where she held roles of increasing responsibility. Ms. Tegan received her BS and MBA from Iona College.

  • Research and Development Leaders

  • Hanne Bak, PhD: Senior Vice President, Preclinical Manufacturing & Process Development

    Hanne Bak, PhD

  • Aris Baras, MD: Senior Vice President, Regeneron Genetics Center

    Aris Baras, MD

  • Ned Braunstein, MD: Senior Vice President, Regulatory Affairs, Pharmacovigilance and Risk Management

    Ned Braunstein, MD

  • Senior Vice President, Preclinical Manufacturing and Process Development

    Hanne Bak, PhD, joined Regeneron in 2004 and serves as Senior Vice President, Preclinical Manufacturing and Process Development (PMPD). She started her career at Regeneron as a research engineer working in the Purification Development group within PMPD and has subsequently held roles of increasing responsibility. Dr. Bak received her BS, MS and PhD in Chemical Engineering from Danmarks Tekniske Universitet (Technical University of Denmark).

  • Senior Vice President, Regeneron Genetics Center

    Aris Baras, MD, joined Regeneron in 2011 and helped found the Regeneron Genetics Center (RGC), where he now serves as Senior Vice President. Previously, he held roles and responsibilities at Regeneron across R&D and business development. Prior to joining Regeneron, Dr. Baras contributed to other biotechnology ventures and conducted research spanning antibody-based therapeutics, cancer research and nanotechnology applications in drug development. Dr. Baras received his BS, MBA and MD from Duke University.

  • Senior Vice President, Regulatory Affairs, Global Patient Safety

    Ned Braunstein, MD, joined Regeneron in 2009, and serves as Senior Vice President, Regulatory Affairs, Global Patient Safety. Prior to joining Regeneron, he worked at Columbia University College of Physicians and Surgeons for 13 years as Assistant and then Associate Professor of Medicine and at Merck & Co., Inc. for nine years in positions of increasing responsibility in Clinical Research, Regulatory Affairs and Global Human Health. Dr. Braunstein received his BS in Medicine and his MD from Northwestern University.

  • Gregory Geba, MD, PhD

    Gregory Geba, MD, PhD

  • Gary Herman, MD

    Gary Herman, MD

  • Bari Kowal

    Bari Kowal

  • Senior Vice President, Global Development Scientific Council

    Gregory Geba, MD, PhD, joined Regeneron in 2013 and serves as Senior Vice President of the Global Development Scientific Council, a group that provides senior scientific input to Regeneron’s therapeutic portfolio of programs. He is a physician-scientist with decades of experience in design, execution and analysis of clinical trials. Previously, Dr. Geba worked at Sanofi, AstraZeneca, Novartis, Merck and Yale University as an Assistant Professor of Medicine. He received his BA in Biology from Brown University, MD from the University of Navarra, completed a Fellowship in Immunology/Pulmonary and Critical Care at Yale University, received an MPH in Epidemiology from The Johns Hopkins University, and his PhD in Molecular Toxicology from Columbia University.

  • Senior Vice President, Early Clinical Development and Experimental Sciences

    Gary Herman, MD, joined Regeneron in 2015 and leads the Early Clinical Development and Experimental Sciences (ECDES) function. Previously, he served in roles of increasing responsibility at Merck, most recently as the Vice President and Head, Early Stage Development. From 2008 to 2015, Dr. Herman was one of only three pharmaceutical industry members on the Executive Committee of the Biomarkers Consortium, a program within the Foundation for the National Institutes of Health. Prior to that, Dr. Herman completed his residency and postdoctoral training at University of California, San Francisco and was an Assistant Professor there before joining industry. He received his BS in Biochemistry and Cell Biology from the University of California, San Diego, and his MD from Harvard Medical School.

  • Senior Vice President, Global Clinical Operations

    Bari Kowal joined Regeneron in 2015 as Head of Global Clinical Operations and now serves as Senior Vice President, Global Development Operations, taking responsibility for Clinical Trial Strategy and Execution and Development Shared Services. She was previously at Pfizer, holding positions of Vice President of Business Operations and Analytics, and Vice President of Strategic Alliance and Development Operations Lead. Ms. Kowal also previously worked in clinical operations on the Clinical Research Organization side of the industry and in clinical research roles at a number of biotechnology companies. She holds a BS in Biology from State University of New York at Binghamton and a MS in Neuroscience from New York University.

  • Johnathan Lancaster, MD, PhD

    Johnathan Lancaster, MD, PhD

  • John Lin, MD, PhD

    John Lin, MD, PhD

  • Israel Lowy, MD, PhD: Senior Vice President, Translational Sciences and Oncology

    Israel Lowy, MD, PhD

  • Senior Vice President, Global Medical Affairs

    Johnathan M. Lancaster, MD, PhD, joined Regeneron in 2019 as a Vice President and now serves as SVP and Head of Global Medical Affairs. Prior to joining Regeneron, Dr. Lancaster served as Chief Medical Officer at Myriad Genetics, Inc., following more than a decade in academics at Moffitt Comprehensive Cancer Center in Tampa as a gynecologic oncologist, molecular genetics researcher, and ultimately President of the Moffitt Medical Group Corporation. Dr. Lancaster received his BSc in Pharmacology and his MD and PhD from the University of Wales in the UK. He received post graduate clinical training in OBGYN and Gynecologic Oncology at the University of Cambridge and Duke University Medical Center.

  • Senior Vice President, Immuno-Oncology and Head of Bispecifics

    John Lin, MD, PhD, joined Regeneron in 2016 and oversees the preclinical bispecific antibody research work in Research and Development across all disease areas. Previously, he worked at Pfizer for 10 years focusing on research and early development of biologics, and before that he worked at Rinat Neuroscience Corporation after completing his postdoctoral fellowship at Genentech. Dr. Lin received his MD from National Taiwan University and his PhD from Harvard University.

  • Senior Vice President, Translational Sciences and Oncology

    Israel Lowy, MD, PhD, joined Regeneron in 2010 as Vice President, and now serves as Senior Vice President, Translational Sciences and Oncology. He is a primary architect of Regeneron’s cancer immunotherapy program. Prior to joining Regeneron, Dr. Lowy was at Medarex for eight years. Before that, he was Assistant Professor of Medicine and Microbiology at Mount Sinai School of Medicine. Dr. Lowy is a licensed physician and has been board certified in internal medicine and infectious diseases. He received his AB in Biochemical Sciences from Princeton University and his MD-PhD in Biochemistry and Molecular Biophysics from Columbia University.

  • Andrew (Drew) Murphy, PhD: Executive Vice President, Research

    Andrew Murphy, PhD

  • William Olson, PhD: Senior Vice President, Therapeutic Proteins

    William Olson, PhD

  • L. Andres Sirulnik, MD, PhD: Senior Vice President, Translational & Clinical Sciences, Hematology

    L. Andres Sirulnik, MD, PhD

  • Executive Vice President, Research

    Andrew Murphy, PhD, joined Regeneron in 1999 as Director of Genomics and Bioinformatics and is now Executive Vice President of Research. In his time at the company, he has led the Gene Discovery and Bioinformatics and Target Discovery groups. Dr. Murphy is a co-inventor of several of Regeneron's key technologies, VelociGene® and VelocImmune®, and continues to lead several Technology Centers and Therapeutic Focus Areas. Prior to joining Regeneron, Dr. Murphy worked for seven years at Cadus Pharmaceuticals. He received his BS in Molecular Biology at the University of Wisconsin, and his PhD in Human Genetics from Columbia University, College of Physicians and Surgeons.

  • Senior Vice President, Therapeutic Proteins

    William Olson, PhD, joined Regeneron in 2013 as Vice President and now serves as Senior Vice President of Therapeutic Proteins, where he is responsible for antibody generation, a key component of drug discovery, through innovative technologies. Before joining Regeneron, he was at Progenics Pharmaceuticals for 19 years. Previously, Dr. Olson was a scientist at MicroGeneSys and Johnson & Johnson’s RW Johnson Pharmaceutical Research Institute. Dr. Olson received his BS in Chemical Engineering at the University of North Dakota, and his PhD in Biochemical Engineering from Massachusetts Institute of Technology

  • Senior Vice President, Translational and Clinical Sciences, Hematology

    L. Andres Sirulnik, MD, PhD joined Regeneron in 2020 and serves as Senior Vice President, Translational and Clinical Sciences, Hematology, leading strategic program direction and clinical sciences work for our early- and late-stage oncologic hematology and late-stage non-oncology hematology portfolios. Before joining Regeneron, Dr. Sirulnik was Chief Medical Officer at Merus N.V., a clinical-stage immuno-oncology company. Prior to Merus N.V., he spent a decade at Novartis in various roles of increasing responsibility, ultimately overseeing the clinical strategy for their immuno-oncology portfolio. Dr. Sirulnik is a licensed physician, formerly practicing at Dana-Farber Cancer Institute and Brigham and Women’s Hospital and was a fellow in hematology/oncology at Mount Sinai Health System. He completed his medical residency at North Shore Long Island Jewish (LIJ) Health System and conducted post doctorate work at Columbia University. He received his PhD in Medicine and Molecular Biology from King’s College, University of Cambridge and his MD from the University of Buenos Aires.

  • Randy Soltys, PhD

    Randy Soltys, PhD

  • Neil Stahl, PhD: Executive Vice President, Research & Development

    Neil Stahl, PhD

  • Gavin Thurston, PhD

    Gavin Thurston, PhD

  • Senior Vice President, Drug Safety and Pharmacometrics

    Randy Soltys, PhD, joined Regeneron in 2011 and now serves as Senior Vice President, Drug Safety and Pharmacometrics, where he is responsible for the Toxicology, Pathology, Preclinical PK/PD and Clinical and Quantitative Pharmacology organizations. Prior to joining Regeneron, he held senior leadership positions in Drug Safety Assessment at Genentech and Bristol-Myers Squibb. Dr. Soltys received his BS in Microbiology from Rutgers University and his PhD in Pharmacology/Toxicology jointly from Rutgers and the University of Medicine and Dentistry of New Jersey, and has been board-certified in Toxicology.

  • Executive Vice President, Research and Development

    Neil Stahl, PhD, joined Regeneron in 1991 and has served as Executive Vice President, Research and Development since January 2015. Dr. Stahl started his career at Regeneron as a Staff Scientist in Discovery Research working on cytokine receptor signaling, and he spearheaded the invention and development of Regeneron’s Trap Technology. Prior to joining Regeneron, Dr. Stahl received his BS degree from Duke University and his PhD in Biochemistry from Brandeis University, then conducted post-doctoral research and was a faculty member at the University of California, San Francisco.

  • Senior Vice President, Oncology Research

    Gavin Thurston, PhD, joined Regeneron in 2001 initially to study the interaction of the VEGF signaling pathway with other angiogenic pathways and to target these pathways for the treatment of cancer. He now serves as Senior Vice President of Oncology Research, and leads the company’s cancer research efforts, including targeting tumor cells with an expanding library of bispecific and costimulatory bispecific antibodies. Prior to joining Regeneron, he was at University of California, San Francisco studying tumor vascular biology. Dr. Thurston received his BS in Physics at Yale University and his PhD in Biophysics from the University of British Columbia.

  • David Weinreich, MD, MBA: Senior Vice President, Global Clinical Development

    David Weinreich, MD, MBA

  • Brian Zambrowicz, PhD: Senior Vice President, Functional Genomics and Chief VelociGene® Operations

    Brian Zambrowicz, PhD

  • Senior Vice President, Global Clinical Development

    David Weinreich, MD, joined Regeneron in 2016 and serves as Senior Vice President, Global Clinical Development. Prior to this role, he was Senior Vice President, Late Stage Clinical Development and Medical Affairs. Dr. Weinreich was previously the Senior Vice President and Head of Global Development for Specialty Medicine at Bayer Pharmaceuticals. Before that, Dr. Weinreich held positions of increasing responsibility focused on the development of oncology molecules at Amgen. Dr. Weinreich also previously served as Vice President of Clinical Affairs at Gene Logic and as an independent consultant, helping small to mid-stage biotechnology companies with drug commercialization. Dr. Weinreich received his BS in computer engineering from Columbia University, his MBA from the McDonough School of Business at Georgetown University and his MD from Boston University School of Medicine.

  • Senior Vice President, Functional Genomics and Chief VelociGene® Operations

    Brian Zambrowicz, PhD, joined Regeneron in 2015 and serves as Senior Vice President, Functional Genomics and Chief VelociGene® Operations. Prior to joining Regeneron, Dr. Zambrowicz held roles of increasing responsibility from 1996 to 2015 at Lexicon Pharmaceuticals, Inc., ultimately serving as Executive Vice President and Chief Scientific Officer. Dr. Zambrowicz received his BS from the University of Wisconsin-Madison and his PhD from the University of Washington.

  • Industrial Operations and Product Supply Leaders

  • Gerald Carreau: Senior Vice President, Commercial Scale Manufacturing & Manufacturing Technology

    Gerald Carreau

  • Scott Carver, PhD: Senior Vice President, Manufacturing and Process Sciences

    Scott Carver, PhD

  • Patrice Gilooly

    Patrice Gilooly

  • Senior Vice President, Commercial Scale Manufacturing and Manufacturing Technology

    Gerald Carreau joined Regeneron in 2008 and serves as Senior Vice President, Commercial Scale Manufacturing and Manufacturing Technology. Prior to Regeneron, Mr. Carreau worked at Novartis (formerly Chiron Corporation). He earned his BS from Virginia Polytechnic Institute and State University.

  • Senior Vice President, Manufacturing and Process Sciences

    Scott Carver, PhD, joined Regeneron in 1998 and serves as Senior Vice President, Manufacturing and Process Sciences. He previously held roles in Process Development and Preclinical Manufacturing, Clinical Manufacturing, and Manufacturing Sciences. Dr. Carver earned his BS in Chemical Engineering from the University of Nevada, Reno and his PhD in Chemical Engineering from Iowa State University.

  • Senior Vice President, Quality Assurance and Operations

    Patrice Gilooly joined Regeneron in 1998 and serves as Senior Vice President, Quality Assurance and Operations. Ms. Gilooly has held positions of increasing responsibility in Validation and Quality Assurance and Operations. Prior to joining Regeneron, she worked at Raytheon Engineers & Construction, Genzyme Corporation and Repligen Corporation. Ms. Gilooly earned a BS in Biology from the University of Massachusetts.

  • Jenny McNay, PhD

    Jenny McNay, PhD

  • Niall O’Leary

    Niall O’Leary

  • Gerald Underwood

    Gerald Underwood

  • Senior Vice President, CMC Regulatory Sciences and Industrial Affairs 

    Jennifer McNay, PhD, joined Regeneron in 2000 and serves as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) Regulatory Sciences and Industrial Affairs. She previously held roles at Regeneron in Preclinical Manufacturing and Process Development, Process Sciences and Combination Products. Prior to joining Regeneron, she worked at Procter and Gamble. Dr. McNay earned her BS in Chemical Engineering from the University of Delaware and her MS and PhD in Chemical Engineering from the University of Virginia.

  • Senior Vice President and Site Head, IOPS Raheen

    Niall O’Leary joined Regeneron in 2012 and serves as Senior Vice President and Site Head of IOPS Raheen. He has held leadership positions of increasing responsibility in Quality, Regulatory Affairs, Program Management and Manufacturing across biological, small molecule and medical device platforms. Prior to joining Regeneron, Mr. O’Leary has worked as an independent consultant and at Pulmatrix, Alkermes, Organogenesis and Merck Serono. Mr. O’Leary received his BS in Biotechnology from Dublin City University, Ireland and his MBA from the Williams College of Business at Xavier University in Cincinnati, Ohio.

  • Senior Vice President, Technical Operations

    Gerald Underwood joined Regeneron in 1995 and serves as Senior Vice President, Technical Operations for the global Industrial Operations & Product Supply organization. He has held leadership roles in Quality, Validation, Regulatory, Internal Manufacturing and Engineering. Before joining Regeneron, Mr. Underwood worked at Fluor Daniel, the Jacobs Engineering Group and Day Laboratories. He holds a BS in Science from the University of California, Davis.

  • Daniel Van Plew: Executive Vice President & General Manager, Industrial Operations & Product Supply

    Daniel Van Plew

  • Ron Wang, PhD

    Ron Wang, PhD

  • Executive Vice President and General Manager, Industrial Operations and Product Supply

    Daniel Van Plew joined Regeneron in 2007 and has served as Executive Vice President and General Manager, Industrial Operations and Product Supply since January 2016. From 2006 to 2007, he served as Executive Vice President, R&D and Technical Operations of Crucell Holland B.V., a global biopharmaceutical company. Between 2004 and 2006, Mr. Van Plew held positions of increasing responsibility at Chiron Biopharmaceuticals, most recently as Senior Director, Vacaville Operations. From 1998 until 2004, he held various managerial positions in the health and life sciences practice at Accenture, Ltd., a management consulting business. Mr. Van Plew received his MS in Chemistry from Penn State University and his MBA from Michigan State University.

  • Senior Vice President, Quality Control

    Ron Wang, PhD, joined Regeneron in 1999 and currently serves as Senior Vice President of Quality Control, leading a global function that leverages strategic business partnerships and automation to provide back-up lab capabilities, protect the supply chain and optimize resources and lab capacity. He has held prior positions at Regeneron in Quality Control and Analytical Sciences, and prior to joining Regeneron, worked at Abbott Laboratories conducting diagnostic assay R&D, bio-process development and commercial assay kit manufacturing. He completed his post-doctoral studies at the University of Pennsylvania. He received his PhD in biochemistry from the University of Delaware and his MBA from the State University of New York at Albany.

  • Leonard S. Schleifer, MD, PhD: Founder, President & Chief Executive Officer

    Leonard S. Schleifer, MD, PhD

  • Co-Founder, President and Chief Executive Officer

    Leonard S. Schleifer, MD, PhD, founded Regeneron in 1988, has been a Director and the company's President and Chief Executive Officer since its inception. He served as Chairman of the Board from 1990 through 1994. Dr. Schleifer, together with Dr. Yancopoulos, has grown Regeneron from a tiny startup into a ~$50 billion market cap company, with a unique science-driven culture, successful drug discovery and development engine and eight FDA-approved medicines. Dr. Schleifer has been recognized as one of Barron’s Best CEOs and as an Ernst & Young Entrepreneur of the Year. He graduated from Cornell University and earned his MD and PhD in Pharmacology from the University of Virginia. Dr. Schleifer is a licensed physician, certified in Neurology by the American Board of Psychiatry and Neurology, and worked as a practicing neurologist before founding Regeneron.

  • George D. Yancopoulos, MD, PhD: Founding Scientist, President & Chief Scientific Officer

    George D. Yancopoulos, MD, PhD

  • Co-Founder, President and Chief Scientific Officer

    George D. Yancopoulos, MD, PhD, has built and managed Regeneron alongside Dr. Schleifer since 1989. Dr. Yancopoulos is currently President and Chief Scientific Officer and has served on the board since 2001. Dr. Yancopoulos, along with key members of his team, is the principal inventor of Regeneron’s eight FDA-approved drugs and foundational technologies, including the TRAP technology, VelociGene® and VelocImmune®. He has been named an Ernst & Young Entrepreneur of the Year and has been pivotal in creating the science-driven, collaborative and highly-productive R&D culture at Regeneron. This unique environment has earned the company widespread recognition, including repeatedly being named one of the "most innovative companies in the world" by Forbes magazine. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos attended the Bronx High School of Science and received his MD and PhD from Columbia University.

  • Maya Bermingham

    Maya Bermingham

  • Senior Vice President, Public Policy & Government Affairs

    Maya Bermingham, JD, joined Regeneron in 2015 and serves as Senior Vice President, Public Policy and Government Affairs. Ms. Bermingham and her Washington, DC-based team play a critical role in helping Regeneron shape and maintain its industry-leading reputation among governmental stakeholders. In 2020, Ms. Bermingham stepped forward to also serve as the company’s interim head of Diversity, Equity and Inclusion (DE&I). Prior to joining Regeneron, Ms. Bermingham held roles of increasing responsibility at PhRMA over a 12 year tenure, following earlier positions at legal firms, and work for Senator Moynihan and the Senate Finance Committee. She received her BA from Harvard University and her JD from New York University.

  • Chris Fenimore

    Chris Fenimore

  • Senior Vice President, Head of Accounting and Controller

    Chris Fenimore joined Regeneron in 2003 and, as the current Head of Accounting and Controller, has global responsibility for SEC reporting, accounting and accounting operations, and internal control over financial reporting, administration of financial systems, accounts payable and payroll. Prior to his current role, he served as Regeneron’s Vice President of Financial Planning, and prior to joining Regeneron, he was Vice President of Finance at Mojave Therapeutics, Inc. He has prior experience in healthcare industry-focused venture capital and investment banking roles, as well as serving as an audit senior at KPMG. Mr. Fenimore holds an MA in Biotechnology from Columbia University, an MBA in Professional Accounting from Rutgers Business School and a BA in Economics from Rutgers University. Mr. Fenimore is a Certified Public Accountant in the State of New York. 

  • Beth F. Holly: Senior Vice President, Associate General Counsel, Chief Compliance Officer

    Beth F. Holly

  • Senior Vice President, Associate General Counsel and Chief Compliance Officer

    Beth F. Holly joined Regeneron in 2008 and serves as Senior Vice President, Associate General Counsel and Chief Compliance Officer. Prior to joining Regeneron, Ms. Holly spent 13 years at Pfizer Inc., where she served in various positions in the Legal Division, culminating in the role of General Counsel - U.S. Pharmaceuticals, followed by 18 months at Keryx Biopharmaceuticals, Inc. as General Counsel and Chief Compliance Officer. In the early days of her legal career, Ms. Holly was a litigation associate at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison, following a judicial clerkship with U.S. District Judge Gerard L. Goettel of the Southern District of New York. Ms. Holly received a BS from Cornell University and a JD degree from Fordham Law School.

  • Nouhad Husseini: Senior Vice President, Business Development

    Nouhad Husseini

  • Senior Vice President, Business Development

    Nouhad Husseini joined Regeneron in 2011 and is head of Business Development, overseeing the company’s efforts to execute new strategic collaborations and licensing agreements. He has nearly 20 years of experience in the biopharmaceutical industry, where he has held a variety of strategic, business development and finance roles, including in Genentech’s Business Development and Corporate Finance departments and in investment banking and equity research at Morgan Stanley and Robertson Stephens. Mr. Husseini received his undergraduate degree in Molecular Biology from Princeton University and MBA from the Wharton School at University of Pennsylvania.

  • Robert E. Landry: Executive Vice President, Finance and Chief Financial Officer

    Robert E. Landry

  • Executive Vice President, Finance and Chief Financial Officer

    Robert E. Landry joined Regeneron in 2013 and serves as Executive Vice President, Finance and Chief Financial Officer. Prior to joining Regeneron, Mr. Landry served as Senior Vice President and Treasurer of Pfizer Inc. Mr. Landry also held a variety of U.S. and international financial and general management positions at Wyeth Pharmaceuticals, Pfizer and PricewaterhouseCoopers LLP, including at Wyeth's Australian and New Zealand affiliates. He holds a BBA in Accounting from the University of Notre Dame.

  • Joseph J. LaRosa: Executive Vice President, General Counsel and Secretary

    Joseph J. LaRosa

  • Executive Vice President, General Counsel and Secretary

    Joseph J. LaRosa joined Regeneron in 2011 and is currently Executive Vice President, General Counsel and Secretary. Prior to joining Regeneron, Mr. LaRosa was Senior Vice President, General Counsel and Secretary at Nycomed U.S., Inc. He also previously served as Vice President, Global Compliance and Legal Affairs at Avon Products, Inc., and held a number of senior legal positions at Schering-Plough Corporation, where he was a corporate officer and served as Vice President, Legal Affairs, and a member of the Operations Management Team. Mr. LaRosa received his JD degree from New York University.

  • Marion McCourt: Senior Vice President, Commercial

    Marion McCourt

  • Senior Vice President, Commercial

    Marion McCourt joined Regeneron in 2018 and serves as Senior Vice President and Head of the Commercial organization. Prior to joining Regeneron, Ms. McCourt worked at Axovant, a clinical-stage biopharmaceutical company, where she was President and Chief Operating Officer. She served as Chief Operating Officer of Medivation until it was acquired by Pfizer Inc. in 2016, and before that held commercial leadership roles at Amgen, including Vice President in U.S. Commercial Operations and Vice President and General Manager responsible for the company’s bone health and primary care business unit. Ms. McCourt began her career and spent 12 years at AstraZeneca, ultimately becoming Chief Operating Officer for AstraZeneca U.S. She received her BS from Lafayette College.

  • Bob McCowan

    Bob McCowan

  • Senior Vice President, IT and Chief Information Officer

    Bob McCowan is Senior Vice President and Chief Information Officer at Regeneron. With over 30 years global experience, Mr. McCowan leads the company’s IT organization and is responsible for global IT strategy supporting Research, Commercial, Cyber Security and Enterprise operations. He has driven an enhanced company focus on big data, innovation and strategic IT investments that support Regeneron’s mission. Mr. McCowan previously worked at international organizations including Amgen, Artemis International, Computer Science Corporation and Lockheed. He earned his MBA with the UK Open University and holds a degree in Electrical Engineering.

  • >Gonzalo Merino, PhD

    Gonzalo Merino, PhD

  • Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel

    Gonzalo Merino, PhD, JD, joined Regeneron in 2013 and now serves as Senior Vice President and Chief Intellectual Property Counsel. He is responsible for protecting Regeneron’s Intellectual Property, including by developing and implementing a comprehensive global IP strategy. Prior to joining Regeneron, Dr. Merino was an Associate General Counsel at Columbia University and a patent attorney at Bryan Cave LLP in New York City. He obtained his JD from Columbia University Law School, where he was a Harlan Fisk Stone Scholar, and his PhD from the Integrated Program in Cellular, Molecular and Biophysical Studies at the Columbia University Graduate School of Arts and Sciences, where he received the Richard C. Parker Award for Outstanding and Innovative Research and a Minority Pre-doctoral Fellowship Award.

  • Hala Mirza: Senior Vice President, Corporate Communications & Citizenship

    Hala Mirza

  • Senior Vice President, Corporate Communications and Citizenship

    Hala Mirza joined Regeneron in 2014 and serves as Senior Vice President, Corporate Communications and Citizenship, leading corporate reputation, internal and external communications, patient advocacy and corporate citizenship. Before joining Regeneron, she was Vice President, Corporate Affairs for R&D and Strategy at Pfizer Inc. Prior to joining Pfizer, Ms. Mirza was Managing Director at W2O Group, a leading healthcare communications agency. She also previously served as Public Relations Officer at the American Red Cross Biomedical Services. Ms. Mirza received her BA from The George Washington University.

  • Sally A. Paull: Senior Vice President, Human Resources

    Sally A. Paull

  • Senior Vice President, Human Resources

    Sally A. Paull joined Regeneron as Senior Vice President, Human Resources in 2016. She was previously Executive Vice President, Chief Human Resources Officer at Inova Health System. Prior to Inova, Ms. Paull was Senior Vice President, Chief Human Resources Officer at Forest Laboratories. Earlier in her career, Ms. Paull served in progressively senior human resources roles at DENYSPLY International. She received her BS from the United States Air Force Academy and her Master’s in International Relations from the University of Delaware.

  • Smita Pillai,

    Smita Pillai

  • Chief Diversity, Equity & Inclusion Officer

    Smita Pillai joined Regeneron as our first Chief Diversity, Equity & Inclusion (DE&I) Officer in 2021. Ms. Pillai has an accomplished global DE&I career spanning Life Sciences, Technology, Financial Services and Media sectors. Most recently she was VP, Global Head of DE&I at Zendesk. Prior to that she was Chief Diversity Officer for Dow Jones, including its flagship brand The Wall Street Journal. Before that, she has led global marketing research, corporate strategy and DE&I efforts at Fortune 50 companies such as Prudential Financial, Johnson & Johnson and ACNielsen. A certified DE&I professional, Ms. Pillai received her BBA from KS School of Management and MBA from Symbiosis International Business School, India.

  • Kerry Reinertsen, PhD: Senior Vice President, Strategic Alliances

    Kerry Reinertsen, PhD

  • Senior Vice President, Strategic Alliances

    Kerry Reinertsen, PhD, joined Regeneron in 2011 and serves as Senior Vice President of Strategic Alliances. Prior to joining Regeneron, she was Chief Business Officer of Constellation Pharmaceuticals. Before this, Dr. Reinertsen served as the Vice President of Corporate Development at Vertex Pharmaceuticals. Dr. Reinertsen started her biotech career at Millennium Pharmaceuticals (now Takeda Oncology) where she held positions of increasing responsibility in business development. Dr. Reinertsen received her PhD in Biological Chemistry and Molecular Pharmacology from Harvard University and her ScB in Molecular Biology and AB in Economics from Brown University.

  • Deb Tegan

    Deborah Tegan

  • Senior Vice President, Strategic Sourcing and Procurement

    Deborah Tegan joined Regeneron in 2006 and serves as Senior Vice President, Strategic Sourcing and Procurement. Prior to joining Regeneron, Ms. Tegan worked at Ciba Specialty Chemicals and then as Senior Director/Head of Procurement at Purdue Pharma L.P., where she held roles of increasing responsibility. Ms. Tegan received her BS and MBA from Iona College.

  • Research and Development Leaders

  • Hanne Bak, PhD: Senior Vice President, Preclinical Manufacturing & Process Development

    Hanne Bak, PhD

  • Senior Vice President, Preclinical Manufacturing and Process Development

    Hanne Bak, PhD, joined Regeneron in 2004 and serves as Senior Vice President, Preclinical Manufacturing and Process Development (PMPD). She started her career at Regeneron as a research engineer working in the Purification Development group within PMPD and has subsequently held roles of increasing responsibility. Dr. Bak received her BS, MS and PhD in Chemical Engineering from Danmarks Tekniske Universitet (Technical University of Denmark).

  • Aris Baras, MD: Senior Vice President, Regeneron Genetics Center

    Aris Baras, MD

  • Senior Vice President, Regeneron Genetics Center

    Aris Baras, MD, joined Regeneron in 2011 and helped found the Regeneron Genetics Center (RGC), where he now serves as Senior Vice President. Previously, he held roles and responsibilities at Regeneron across R&D and business development. Prior to joining Regeneron, Dr. Baras contributed to other biotechnology ventures and conducted research spanning antibody-based therapeutics, cancer research and nanotechnology applications in drug development. Dr. Baras received his BS, MBA and MD from Duke University.

  • Ned Braunstein, MD: Senior Vice President, Regulatory Affairs, Pharmacovigilance and Risk Management

    Ned Braunstein, MD

  • Senior Vice President, Regulatory Affairs, Global Patient Safety

    Ned Braunstein, MD, joined Regeneron in 2009, and serves as Senior Vice President, Regulatory Affairs, Global Patient Safety. Prior to joining Regeneron, he worked at Columbia University College of Physicians and Surgeons for 13 years as Assistant and then Associate Professor of Medicine and at Merck & Co., Inc. for nine years in positions of increasing responsibility in Clinical Research, Regulatory Affairs and Global Human Health. Dr. Braunstein received his BS in Medicine and his MD from Northwestern University.

  • Gregory Geba, MD, PhD

    Gregory Geba, MD, PhD

  • Senior Vice President, Global Development Scientific Council

    Gregory Geba, MD, PhD, joined Regeneron in 2013 and serves as Senior Vice President of the Global Development Scientific Council, a group that provides senior scientific input to Regeneron’s therapeutic portfolio of programs. He is a physician-scientist with decades of experience in design, execution and analysis of clinical trials. Previously, Dr. Geba worked at Sanofi, AstraZeneca, Novartis, Merck and Yale University as an Assistant Professor of Medicine. He received his BA in Biology from Brown University, MD from the University of Navarra, completed a Fellowship in Immunology/Pulmonary and Critical Care at Yale University, received an MPH in Epidemiology from The Johns Hopkins University, and his PhD in Molecular Toxicology from Columbia University.

  • Gary Herman, MD

    Gary Herman, MD

  • Senior Vice President, Early Clinical Development and Experimental Sciences

    Gary Herman, MD, joined Regeneron in 2015 and leads the Early Clinical Development and Experimental Sciences (ECDES) function. Previously, he served in roles of increasing responsibility at Merck, most recently as the Vice President and Head, Early Stage Development. From 2008 to 2015, Dr. Herman was one of only three pharmaceutical industry members on the Executive Committee of the Biomarkers Consortium, a program within the Foundation for the National Institutes of Health. Prior to that, Dr. Herman completed his residency and postdoctoral training at University of California, San Francisco and was an Assistant Professor there before joining industry. He received his BS in Biochemistry and Cell Biology from the University of California, San Diego, and his MD from Harvard Medical School.

  • Bari Kowal

    Bari Kowal

  • Senior Vice President, Global Clinical Operations

    Bari Kowal joined Regeneron in 2015 as Head of Global Clinical Operations and now serves as Senior Vice President, Global Development Operations, taking responsibility for Clinical Trial Strategy and Execution and Development Shared Services. She was previously at Pfizer, holding positions of Vice President of Business Operations and Analytics, and Vice President of Strategic Alliance and Development Operations Lead. Ms. Kowal also previously worked in clinical operations on the Clinical Research Organization side of the industry and in clinical research roles at a number of biotechnology companies. She holds a BS in Biology from State University of New York at Binghamton and a MS in Neuroscience from New York University.

  • Johnathan Lancaster, MD, PhD

    Johnathan Lancaster, MD, PhD

  • Senior Vice President, Global Medical Affairs

    Johnathan M. Lancaster, MD, PhD, joined Regeneron in 2019 as a Vice President and now serves as SVP and Head of Global Medical Affairs. Prior to joining Regeneron, Dr. Lancaster served as Chief Medical Officer at Myriad Genetics, Inc., following more than a decade in academics at Moffitt Comprehensive Cancer Center in Tampa as a gynecologic oncologist, molecular genetics researcher, and ultimately President of the Moffitt Medical Group Corporation. Dr. Lancaster received his BSc in Pharmacology and his MD and PhD from the University of Wales in the UK. He received post graduate clinical training in OBGYN and Gynecologic Oncology at the University of Cambridge and Duke University Medical Center.

  • John Lin, MD, PhD

    John Lin, MD, PhD

  • Senior Vice President, Immuno-Oncology and Head of Bispecifics

    John Lin, MD, PhD, joined Regeneron in 2016 and oversees the preclinical bispecific antibody research work in Research and Development across all disease areas. Previously, he worked at Pfizer for 10 years focusing on research and early development of biologics, and before that he worked at Rinat Neuroscience Corporation after completing his postdoctoral fellowship at Genentech. Dr. Lin received his MD from National Taiwan University and his PhD from Harvard University.

  • Israel Lowy, MD, PhD: Senior Vice President, Translational Sciences and Oncology

    Israel Lowy, MD, PhD

  • Senior Vice President, Translational Sciences and Oncology

    Israel Lowy, MD, PhD, joined Regeneron in 2010 as Vice President, and now serves as Senior Vice President, Translational Sciences and Oncology. He is a primary architect of Regeneron’s cancer immunotherapy program. Prior to joining Regeneron, Dr. Lowy was at Medarex for eight years. Before that, he was Assistant Professor of Medicine and Microbiology at Mount Sinai School of Medicine. Dr. Lowy is a licensed physician and has been board certified in internal medicine and infectious diseases. He received his AB in Biochemical Sciences from Princeton University and his MD-PhD in Biochemistry and Molecular Biophysics from Columbia University.

  • Andrew (Drew) Murphy, PhD: Executive Vice President, Research

    Andrew Murphy, PhD

  • Executive Vice President, Research

    Andrew Murphy, PhD, joined Regeneron in 1999 as Director of Genomics and Bioinformatics and is now Executive Vice President of Research. In his time at the company, he has led the Gene Discovery and Bioinformatics and Target Discovery groups. Dr. Murphy is a co-inventor of several of Regeneron's key technologies, VelociGene® and VelocImmune®, and continues to lead several Technology Centers and Therapeutic Focus Areas. Prior to joining Regeneron, Dr. Murphy worked for seven years at Cadus Pharmaceuticals. He received his BS in Molecular Biology at the University of Wisconsin, and his PhD in Human Genetics from Columbia University, College of Physicians and Surgeons.

  • William Olson, PhD: Senior Vice President, Therapeutic Proteins

    William Olson, PhD

  • Senior Vice President, Therapeutic Proteins

    William Olson, PhD, joined Regeneron in 2013 as Vice President and now serves as Senior Vice President of Therapeutic Proteins, where he is responsible for antibody generation, a key component of drug discovery, through innovative technologies. Before joining Regeneron, he was at Progenics Pharmaceuticals for 19 years. Previously, Dr. Olson was a scientist at MicroGeneSys and Johnson & Johnson’s RW Johnson Pharmaceutical Research Institute. Dr. Olson received his BS in Chemical Engineering at the University of North Dakota, and his PhD in Biochemical Engineering from Massachusetts Institute of Technology

  • L. Andres Sirulnik, MD, PhD: Senior Vice President, Translational & Clinical Sciences, Hematology

    L. Andres Sirulnik, MD, PhD

  • Senior Vice President, Translational and Clinical Sciences, Hematology

    L. Andres Sirulnik, MD, PhD joined Regeneron in 2020 and serves as Senior Vice President, Translational and Clinical Sciences, Hematology, leading strategic program direction and clinical sciences work for our early- and late-stage oncologic hematology and late-stage non-oncology hematology portfolios. Before joining Regeneron, Dr. Sirulnik was Chief Medical Officer at Merus N.V., a clinical-stage immuno-oncology company. Prior to Merus N.V., he spent a decade at Novartis in various roles of increasing responsibility, ultimately overseeing the clinical strategy for their immuno-oncology portfolio. Dr. Sirulnik is a licensed physician, formerly practicing at Dana-Farber Cancer Institute and Brigham and Women’s Hospital and was a fellow in hematology/oncology at Mount Sinai Health System. He completed his medical residency at North Shore Long Island Jewish (LIJ) Health System and conducted post doctorate work at Columbia University. He received his PhD in Medicine and Molecular Biology from King’s College, University of Cambridge and his MD from the University of Buenos Aires.

  • Randy Soltys, PhD

    Randy Soltys, PhD

  • Senior Vice President, Drug Safety and Pharmacometrics

    Randy Soltys, PhD, joined Regeneron in 2011 and now serves as Senior Vice President, Drug Safety and Pharmacometrics, where he is responsible for the Toxicology, Pathology, Preclinical PK/PD and Clinical and Quantitative Pharmacology organizations. Prior to joining Regeneron, he held senior leadership positions in Drug Safety Assessment at Genentech and Bristol-Myers Squibb. Dr. Soltys received his BS in Microbiology from Rutgers University and his PhD in Pharmacology/Toxicology jointly from Rutgers and the University of Medicine and Dentistry of New Jersey, and has been board-certified in Toxicology.

  • Neil Stahl, PhD: Executive Vice President, Research & Development

    Neil Stahl, PhD

  • Executive Vice President, Research and Development

    Neil Stahl, PhD, joined Regeneron in 1991 and has served as Executive Vice President, Research and Development since January 2015. Dr. Stahl started his career at Regeneron as a Staff Scientist in Discovery Research working on cytokine receptor signaling, and he spearheaded the invention and development of Regeneron’s Trap Technology. Prior to joining Regeneron, Dr. Stahl received his BS degree from Duke University and his PhD in Biochemistry from Brandeis University, then conducted post-doctoral research and was a faculty member at the University of California, San Francisco.

  • Gavin Thurston, PhD

    Gavin Thurston, PhD

  • Senior Vice President, Oncology Research

    Gavin Thurston, PhD, joined Regeneron in 2001 initially to study the interaction of the VEGF signaling pathway with other angiogenic pathways and to target these pathways for the treatment of cancer. He now serves as Senior Vice President of Oncology Research, and leads the company’s cancer research efforts, including targeting tumor cells with an expanding library of bispecific and costimulatory bispecific antibodies. Prior to joining Regeneron, he was at University of California, San Francisco studying tumor vascular biology. Dr. Thurston received his BS in Physics at Yale University and his PhD in Biophysics from the University of British Columbia.

  • David Weinreich, MD, MBA: Senior Vice President, Global Clinical Development

    David Weinreich, MD, MBA

  • Senior Vice President, Global Clinical Development

    David Weinreich, MD, joined Regeneron in 2016 and serves as Senior Vice President, Global Clinical Development. Prior to this role, he was Senior Vice President, Late Stage Clinical Development and Medical Affairs. Dr. Weinreich was previously the Senior Vice President and Head of Global Development for Specialty Medicine at Bayer Pharmaceuticals. Before that, Dr. Weinreich held positions of increasing responsibility focused on the development of oncology molecules at Amgen. Dr. Weinreich also previously served as Vice President of Clinical Affairs at Gene Logic and as an independent consultant, helping small to mid-stage biotechnology companies with drug commercialization. Dr. Weinreich received his BS in computer engineering from Columbia University, his MBA from the McDonough School of Business at Georgetown University and his MD from Boston University School of Medicine.

  • Brian Zambrowicz, PhD: Senior Vice President, Functional Genomics and Chief VelociGene® Operations

    Brian Zambrowicz, PhD

  • Senior Vice President, Functional Genomics and Chief VelociGene® Operations

    Brian Zambrowicz, PhD, joined Regeneron in 2015 and serves as Senior Vice President, Functional Genomics and Chief VelociGene® Operations. Prior to joining Regeneron, Dr. Zambrowicz held roles of increasing responsibility from 1996 to 2015 at Lexicon Pharmaceuticals, Inc., ultimately serving as Executive Vice President and Chief Scientific Officer. Dr. Zambrowicz received his BS from the University of Wisconsin-Madison and his PhD from the University of Washington.

  • Industrial Operations and Product Supply Leaders

  • Gerald Carreau: Senior Vice President, Commercial Scale Manufacturing & Manufacturing Technology

    Gerald Carreau

  • Senior Vice President, Commercial Scale Manufacturing and Manufacturing Technology

    Gerald Carreau joined Regeneron in 2008 and serves as Senior Vice President, Commercial Scale Manufacturing and Manufacturing Technology. Prior to Regeneron, Mr. Carreau worked at Novartis (formerly Chiron Corporation). He earned his BS from Virginia Polytechnic Institute and State University.

  • Scott Carver, PhD: Senior Vice President, Manufacturing and Process Sciences

    Scott Carver, PhD

  • Senior Vice President, Manufacturing and Process Sciences

    Scott Carver, PhD, joined Regeneron in 1998 and serves as Senior Vice President, Manufacturing and Process Sciences. He previously held roles in Process Development and Preclinical Manufacturing, Clinical Manufacturing, and Manufacturing Sciences. Dr. Carver earned his BS in Chemical Engineering from the University of Nevada, Reno and his PhD in Chemical Engineering from Iowa State University.

  • Patrice Gilooly

    Patrice Gilooly

  • Senior Vice President, Quality Assurance and Operations

    Patrice Gilooly joined Regeneron in 1998 and serves as Senior Vice President, Quality Assurance and Operations. Ms. Gilooly has held positions of increasing responsibility in Validation and Quality Assurance and Operations. Prior to joining Regeneron, she worked at Raytheon Engineers & Construction, Genzyme Corporation and Repligen Corporation. Ms. Gilooly earned a BS in Biology from the University of Massachusetts.

  • Jenny McNay, PhD

    Jenny McNay, PhD

  • Senior Vice President, CMC Regulatory Sciences and Industrial Affairs 

    Jennifer McNay, PhD, joined Regeneron in 2000 and serves as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) Regulatory Sciences and Industrial Affairs. She previously held roles at Regeneron in Preclinical Manufacturing and Process Development, Process Sciences and Combination Products. Prior to joining Regeneron, she worked at Procter and Gamble. Dr. McNay earned her BS in Chemical Engineering from the University of Delaware and her MS and PhD in Chemical Engineering from the University of Virginia.

  • Niall O’Leary

    Niall O’Leary

  • Senior Vice President, Quality Control

    Niall O’Leary joined Regeneron in 2012 and serves as Senior Vice President and Site Head of IOPS Raheen. He has held leadership positions of increasing responsibility in Quality, Regulatory Affairs, Program Management and Manufacturing across biological, small molecule and medical device platforms. Prior to joining Regeneron, Mr. O’Leary has worked as an independent consultant and at Pulmatrix, Alkermes, Organogenesis and Merck Serono. Mr. O’Leary received his BS in Biotechnology from Dublin City University, Ireland and his MBA from the Williams College of Business at Xavier University in Cincinnati, Ohio.

  • Gerald Underwood

    Gerald Underwood

  • Senior Vice President, Technical Operations

    Gerald Underwood joined Regeneron in 1995 and serves as Senior Vice President, Technical Operations for the global Industrial Operations & Product Supply organization. He has held leadership roles in Quality, Validation, Regulatory, Internal Manufacturing and Engineering. Before joining Regeneron, Mr. Underwood worked at Fluor Daniel, the Jacobs Engineering Group and Day Laboratories. He holds a BS in Science from the University of California, Davis.

  • Daniel Van Plew: Executive Vice President & General Manager, Industrial Operations & Product Supply

    Daniel Van Plew

  • Executive Vice President and General Manager, Industrial Operations and Product Supply

    Daniel Van Plew joined Regeneron in 2007 and has served as Executive Vice President and General Manager, Industrial Operations and Product Supply since January 2016. From 2006 to 2007, he served as Executive Vice President, R&D and Technical Operations of Crucell Holland B.V., a global biopharmaceutical company. Between 2004 and 2006, Mr. Van Plew held positions of increasing responsibility at Chiron Biopharmaceuticals, most recently as Senior Director, Vacaville Operations. From 1998 until 2004, he held various managerial positions in the health and life sciences practice at Accenture, Ltd., a management consulting business. Mr. Van Plew received his MS in Chemistry from Penn State University and his MBA from Michigan State University.

  • Ron Wang, PhD

    Ron Wang, PhD

  • Senior Vice President, Quality Control

    Ron Wang, PhD, joined Regeneron in 1999 and currently serves as Senior Vice President of Quality Control, leading a global function that leverages strategic business partnerships and automation to provide back-up lab capabilities, protect the supply chain and optimize resources and lab capacity. He has held prior positions at Regeneron in Quality Control and Analytical Sciences, and prior to joining Regeneron, worked at Abbott Laboratories conducting diagnostic assay R&D, bio-process development and commercial assay kit manufacturing. He completed his post-doctoral studies at the University of Pennsylvania. He received his PhD in biochemistry from the University of Delaware and his MBA from the State University of New York at Albany.